EP2212694A4 - Verfahren zur identifizierung sicherer nmda-rezeptor-antagonisten - Google Patents

Verfahren zur identifizierung sicherer nmda-rezeptor-antagonisten

Info

Publication number
EP2212694A4
EP2212694A4 EP08847388A EP08847388A EP2212694A4 EP 2212694 A4 EP2212694 A4 EP 2212694A4 EP 08847388 A EP08847388 A EP 08847388A EP 08847388 A EP08847388 A EP 08847388A EP 2212694 A4 EP2212694 A4 EP 2212694A4
Authority
EP
European Patent Office
Prior art keywords
methods
receptor antagonists
nmda receptor
identifying safe
safe nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08847388A
Other languages
English (en)
French (fr)
Other versions
EP2212694A2 (de
Inventor
Raymond J Dingledine
Stephen F Traynelis
Dennis C Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of EP2212694A2 publication Critical patent/EP2212694A2/de
Publication of EP2212694A4 publication Critical patent/EP2212694A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP08847388A 2007-11-06 2008-11-06 Verfahren zur identifizierung sicherer nmda-rezeptor-antagonisten Withdrawn EP2212694A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592407P 2007-11-06 2007-11-06
US98592207P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (2)

Publication Number Publication Date
EP2212694A2 EP2212694A2 (de) 2010-08-04
EP2212694A4 true EP2212694A4 (de) 2011-10-12

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08847388A Withdrawn EP2212694A4 (de) 2007-11-06 2008-11-06 Verfahren zur identifizierung sicherer nmda-rezeptor-antagonisten

Country Status (12)

Country Link
EP (1) EP2212694A4 (de)
JP (1) JP2011503013A (de)
KR (1) KR20100100858A (de)
CN (1) CN101918832A (de)
AU (1) AU2008323877A1 (de)
BR (1) BRPI0820406A2 (de)
CA (1) CA2704475A1 (de)
EA (1) EA201070571A1 (de)
IL (1) IL205432A0 (de)
MX (1) MX2010004971A (de)
WO (1) WO2009061935A2 (de)
ZA (1) ZA201003724B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159960A (ja) * 2011-06-08 2014-09-04 Astellas Pharma Inc 慢性疼痛モデル動物における自発痛行動自動測定法
KR20180015158A (ko) * 2015-05-22 2018-02-12 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
EP3383429B1 (de) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonisten zur behandlung von krebs angiogenese
CN111960514A (zh) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 一种用于脱硫废水浓缩的电渗析智能控制系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
KR20030063765A (ko) * 2002-01-24 2003-07-31 엘지전자 주식회사 광픽업용 대물렌즈
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN1894279A (zh) * 2003-12-16 2007-01-10 安万特药物公司 分泌性神经凋亡抑制蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOTT D D ET AL: "Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition.", NATURE NEUROSCIENCE DEC 1998 LNKD- PUBMED:10196581, vol. 1, no. 8, December 1998 (1998-12-01), pages 659 - 667, XP002657901, ISSN: 1097-6256 *
TAKIZAWA S ET AL: "THE EFFECTS OF A COMPETITIVE NMDA RECEPTOR ANTAGONIST CGS-19755 ON CEREBRAL BLOOD FLOW AND PH IN FOCAL ISCHEMIA", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 11, no. 5, 1991, pages 786 - 793, XP002657900, ISSN: 0271-678X *

Also Published As

Publication number Publication date
KR20100100858A (ko) 2010-09-15
ZA201003724B (en) 2013-10-30
CN101918832A (zh) 2010-12-15
IL205432A0 (en) 2010-12-30
EP2212694A2 (de) 2010-08-04
BRPI0820406A2 (pt) 2015-05-19
JP2011503013A (ja) 2011-01-27
CA2704475A1 (en) 2009-05-14
WO2009061935A3 (en) 2009-08-20
WO2009061935A2 (en) 2009-05-14
AU2008323877A1 (en) 2009-05-14
EA201070571A1 (ru) 2010-12-30
MX2010004971A (es) 2010-07-28

Similar Documents

Publication Publication Date Title
HK1182441A1 (zh) 用於檢測細胞內截短受體的方法
GB2456192B (en) Dust-separating apparatus
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
PT2129654E (pt) Antagonistas do receptor de glucagina
PT2927224T (pt) Antagonistas de receptores
EP2244575A4 (de) Angiotensin-ii-rezeptorantagonisten
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
ZA201103156B (en) Isonicotinamide orexin receptor antagonists
EP2184278A4 (de) P2x4-rezeptorantagonist
EP2058304A4 (de) P2x4-rezeptorantagonist
EP2427430A4 (de) 5-oxo-ete-rezeptorantagonistverbindungen
ZA201006587B (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
EP2350024A4 (de) Verbessertes verfahren zur herstellung von endothelin-rezeptorantagonisten
IL212545A0 (en) Toll-like receptor 3 antagonists
EP2312947A4 (de) Trpv4-antagonisten
HK1203481A1 (en) Glucagon antagonists
EP2191830A4 (de) Feststoffpräparat mit einem npyy5-rezeptor-antagonisten
HK1163063A1 (en) Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity 5-ht2b -3-
EP2254413A4 (de) Imidazobenzazepin-cgrp-rezeptorantagonisten
EP2153736A4 (de) Neuer leukotrien-rezeptor-antagonist
ZA201003724B (en) Methods of identifying safe nmda receptor antagonists
EP2341919A4 (de) Cgrp-rezeptorantagonisten
EP2340025A4 (de) Cgrp-rezeptorantagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DINGLEDINE, RAYMOND, J.

Inventor name: LIOTTA, DENNIS, C.

Inventor name: TRAYNELIS, STEPHEN, F.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146314

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/15 20060101ALI20110901BHEP

Ipc: G01N 33/84 20060101ALI20110901BHEP

Ipc: G01N 33/50 20060101ALI20110901BHEP

Ipc: G01N 33/48 20060101AFI20110901BHEP

Ipc: G01N 31/22 20060101ALI20110901BHEP

Ipc: G01N 31/20 20060101ALI20110901BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110912

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130107

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130518

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1146314

Country of ref document: HK